![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Completed |
Unique ID issued by UMIN | UMIN000012448 |
Receipt No. | R000014558 |
Scientific Title | Effects of fermented dairy product on glucose metabolism in pre-diabetic subjects: a double blind, placebo-controlled study |
Date of disclosure of the study information | 2013/11/29 |
Last modified on | 2014/06/30 |
Basic information | ||
Public title | Effects of fermented dairy product on glucose metabolism in pre-diabetic subjects: a double blind, placebo-controlled study | |
Acronym | Effects of fermented dairy product in pre-diabetic subjects | |
Scientific Title | Effects of fermented dairy product on glucose metabolism in pre-diabetic subjects: a double blind, placebo-controlled study | |
Scientific Title:Acronym | Effects of fermented dairy product in pre-diabetic subjects | |
Region |
|
Condition | ||
Condition | impaired glucose tolerance | |
Classification by specialty |
|
|
Classification by malignancy | Others | |
Genomic information | NO |
Objectives | |
Narrative objectives1 | This study aims to evaluate the effects of ingestion of fermented dairy product containing lactic acid bacteria for 8 consecutive weeks on glucose metabolism in men with body mass index >= 25 and impaired glucose tolerance (IGT). |
Basic objectives2 | Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | Glucose tolerance (maximum plasma glucose level, area under the curve of plasma glucose, glucose spike (the difference between maximum plasma glucose and fasting plasma glucose), and plasma levels of glucose (30, 60, 90 and 120 min) during 75-g oral glucose tolerance test (OGTT))
The effects on the primary outcomes are evaluated not only in all subjects but also in the subgroup with impaired early insulin responses (insulinogenic index <0.4). |
Key secondary outcomes | fasting plasma glucose, insulinogenic index (II),homeostasis model assessment of beta-cell function (HOMA-beta), Matsuda index, homeostasis model assessment-insulin resistance (HOMA-IR), serum insulin level during OGTT, glycoalbumin, HbA1c, serum cholesterol level (non-HDL cholesterol, LDL cholesterol, total cholesterol, and HDL cholesterol)
The effects on the secondary outcomes are evaluated not only in all subjects but also in the subgroup with impaired early insulin responses (insulinogenic index <0.4). |
Base | |
Study type | Interventional |
Study design | |
Basic design | Parallel |
Randomization | Randomized |
Randomization unit | |
Blinding | Double blind -all involved are blinded |
Control | Placebo |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Prevention | |
Type of intervention |
|
|
Interventions/Control_1 | fermented dairy product containing lactic acid bacteria | |
Interventions/Control_2 | placebo (non-fermented dairy product) | |
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male | |||
Key inclusion criteria | 1) An age 20 years or older and up to 64 years
2) A BMI of 25 or more 3) A 1-hour plasma glucose level during OGTT of 180 mg/dL or more 4) A 2-hour plasma glucose level during OGTT of about 140 to 199 mg/dL |
|||
Key exclusion criteria | 1) Subjects who consume lactic acid bacteria beverage, lactic acid bacteria -rich food or lactic acid bacteria preparation more than 3 times a week
2) Subjects routinely taking medicine or health food which may influence glucose metabolism 3) Subjects who are under medication which may influence the outcome of the study 4) Subjects with a history of serious disease, e.g., liver disease, kidney disease, hypertension, or ischemic heart disease 5) Subjects with allergies to dairy products used in the study 6) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination 7) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study 8) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire 9) Subjects who are judged as unsuitable for the study by physician for other reason |
|||
Target sample size | 100 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Nishi-Shinjyuku Kisaragi Clinic | ||||||
Division name | none | ||||||
Zip code | |||||||
Address | 6-6-2 Nishishinjuku, Sinjuku-ku, Tokyo | ||||||
TEL | 03-3344-0529 | ||||||
saiyo@kisa-cl.com |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | TTC Co., Ltd. | ||||||
Division name | Clinical Research Planning Department | ||||||
Zip code | |||||||
Address | 1-20-2 Ebisunishi, shibuya-ku, Tokyo | ||||||
TEL | 03-5459-5329 | ||||||
Homepage URL | |||||||
ttcpwr2001@ttc-tokyo.co.jp |
Sponsor | |
Institute | Nishi-Shinjyuku Kisaragi Clinic |
Institute | |
Department |
Funding Source | |
Organization | TTC Co., Ltd. |
Organization | |
Division | |
Category of Funding Organization | Profit organization |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | |
Address | |
Tel | |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Completed | ||||||
Date of protocol fixation |
|
||||||
Date of IRB | |||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014558 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |